ZAI LAB LIMITED Revenue
ZAI LAB LIMITED (ZLAB) reported Revenue of $106.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-06
- ZAI LAB LIMITED revenues for the quarter ending 2026-06-30 was $106.31M, a 3.33% decline year-over-year.
- ZAI LAB LIMITED revenues for the quarter ending 2026-03-31 was $99.61M, a 6.46% decline year-over-year.
- ZAI LAB LIMITED revenues for the quarter ending 2025-12-31 was $127.60M, a 16.99% increase year-over-year.
- ZAI LAB LIMITED revenues for the quarter ending 2025-09-30 was $116.09M, a 13.52% increase year-over-year.
- ZAI LAB LIMITED revenues for fiscal 2025 was $460.16M, a 15.33% increase from fiscal 2024.
- ZAI LAB LIMITED revenues for fiscal 2024 was $398.99M, a 49.59% increase from fiscal 2023.
- ZAI LAB LIMITED revenues for fiscal 2023 was $266.72M, a 24.03% increase from fiscal 2022.
- ZAI LAB LIMITED revenues for fiscal 2022 was $215.04M, a 49.01% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $106.31M 10-Q · filed 2026-08-06 | $205.92M 10-Q · filed 2026-08-06 | $333.52M derived: sum of 3 quarters · filed 2026-08-06 | $449.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $99.61M 10-Q · filed 2026-05-07 | $227.21M derived: sum of 2 quarters · filed 2026-05-07 | $343.30M derived: sum of 3 quarters · filed 2026-05-07 | $453.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $127.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $243.69M derived: sum of 2 quarters · filed 2026-02-26 | $353.67M derived: sum of 3 quarters · filed 2026-08-06 | $460.16M 10-K · filed 2026-02-26 |
| 2025-09-30 | $116.09M 10-Q · filed 2025-11-06 | $226.07M derived: sum of 2 quarters · filed 2026-08-06 | $332.56M 10-Q · filed 2025-11-06 | $441.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $109.98M 10-Q · filed 2026-08-06 | $216.46M 10-Q · filed 2026-08-06 | $325.53M derived: sum of 3 quarters · filed 2026-08-06 | $427.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $106.49M 10-Q · filed 2026-05-07 | $215.56M derived: sum of 2 quarters · filed 2026-05-07 | $317.82M derived: sum of 3 quarters · filed 2026-05-07 | $418.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $109.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $211.34M derived: sum of 2 quarters · filed 2026-02-26 | $311.84M derived: sum of 3 quarters · filed 2026-02-26 | $398.99M 10-K · filed 2026-02-26 |
| 2024-09-30 | $102.27M 10-Q · filed 2025-11-06 | $202.77M derived: sum of 2 quarters · filed 2025-11-06 | $289.92M 10-Q · filed 2025-11-06 | $355.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $100.50M 10-Q · filed 2025-08-07 | $187.65M 10-Q · filed 2025-08-07 | $253.48M derived: sum of 3 quarters · filed 2026-02-26 | $322.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $87.15M 10-Q · filed 2025-05-08 | $152.98M derived: sum of 2 quarters · filed 2026-02-26 | $222.21M derived: sum of 3 quarters · filed 2026-02-26 | $291.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $65.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $135.06M derived: sum of 2 quarters · filed 2026-02-26 | $203.92M derived: sum of 3 quarters · filed 2026-02-26 | $266.72M 10-K · filed 2026-02-26 |
| 2023-09-30 | $69.23M 10-Q · filed 2024-11-12 | $138.09M derived: sum of 2 quarters · filed 2024-11-12 | $200.89M 10-Q · filed 2024-11-12 | $263.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $68.86M 10-Q · filed 2024-08-06 | $131.66M 10-Q · filed 2024-08-06 | $194.26M derived: sum of 3 quarters · filed 2025-02-27 | $251.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $62.80M 10-Q · filed 2023-05-09 | $125.40M derived: sum of 2 quarters · filed 2025-02-27 | $182.94M derived: sum of 3 quarters · filed 2025-02-27 | $231.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $62.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $120.14M derived: sum of 2 quarters · filed 2025-02-27 | $168.32M derived: sum of 3 quarters · filed 2025-02-27 | $215.04M 10-K · filed 2025-02-27 |
| 2022-09-30 | $57.54M 10-Q · filed 2023-11-07 | $105.72M derived: sum of 2 quarters · filed 2023-11-07 | $152.44M 10-Q · filed 2023-11-07 | $196.61M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $48.18M 10-Q · filed 2023-08-07 | $94.90M 10-Q · filed 2023-08-07 | $139.07M derived: sum of 3 quarters · filed 2024-02-27 | $182.17M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $46.72M 10-Q · filed 2023-05-09 | $90.89M derived: sum of 2 quarters · filed 2024-02-27 | $134.00M derived: sum of 3 quarters · filed 2024-02-27 | $170.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $44.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $87.27M derived: sum of 2 quarters · filed 2024-02-27 | $124.21M derived: sum of 3 quarters · filed 2024-02-27 | $144.31M 10-K · filed 2024-02-27 |
| 2021-09-30 | $43.10M 10-Q · filed 2022-11-09 | $80.04M derived: sum of 2 quarters · filed 2022-11-09 | $100.14M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $36.94M 10-Q · filed 2022-08-09 | $57.04M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $20.10M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $48.96M 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $12.98M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |